Vaso Corp

Vaso Corp maintains a strong liquidity position with $35.05 million in cash and equivalents, representing 39.6% of total assets, and a current ratio of 1.59, well above the industry median of 1.2. The company's debt-to-equity ratio of 0.01 is significantly lower than the 0.3 median for its industry, indicating minimal leverage risk. Profitability metrics show mixed performance. Return on equity (ROE) of 5.33% is below the 8.5% median for Advanced Medical Equipment & Technology firms, while return on assets (ROA) of 1.78% lags the 3.2% industry median. Operating income of -$2.06 million in the latest period highlights margin pressure despite $54.67 million in gross profit. Revenue concentration analysis reveals a three-segment structure: IT services (42% of revenue), Professional sales (35%), and Equipment (23%). Geographic exposure is not disclosed in the latest filing, but international operations are managed through Vasomedical Global Corp, suggesting moderate diversification risk. Growth trajectory shows a 12.4% year-over-year revenue increase to $89.1 million, driven by IT segment expansion. However, operating cash flow of $9.27 million and free cash flow of $1.5 million suggest limited capacity for aggressive reinvestment without external financing. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure remains conservative, with long-term debt of $289,000 and no near-term debt maturities. Dilution potential is minimal given equal basic and diluted share counts of 175.95 million. Recent 10-K filings disclose no material litigation or regulatory actions. Management highlighted IT segment growth in Q4 earnings calls, though operating losses persist in the Equipment segment. No significant capital raising or asset sales were reported in the last 12 months.